Cyclin D1 is aberrantly expressed in many types of
cancers, including
breast cancer. High levels of
cyclin D1b, the truncated
isoform of
cyclin D1, have been reported to be associated with a poor prognosis for
breast cancer patients. In the present study, we used
siRNA to target
cyclin D1b overexpression and assessed its ability to suppress
breast cancer growth in nude mice.
Cyclin D1b
siRNA effectively inhibited overexpression of
cyclin D1b. Depletion of
cyclin D1b promoted apoptosis of
cyclin D1b-overexpressing cells and blocked their proliferation and transformation phenotypes. Notably,
cyclin D1b overexpression is correlated with triple-negative basal-like breast
cancers, which lack specific therapeutic targets. Administration of
cyclin D1b
siRNA inhibited
breast tumor growth in nude mice and
cyclin D1b
siRNA synergistically enhanced the cell killing effects of
doxorubicin in cell culture, with this combination significantly suppressing
tumor growth in the mouse model. In conclusion, the results indicate that
cyclin D1b, which is overexpressed in
breast cancer, may serve as a novel and effective therapeutic target. More importantly, the present study clearly demonstrated a very promising therapeutic potential for
cyclin D1b
siRNA in the treatment of
cyclin D1b-overexpressing breast
cancers, including the very malignant
triple-negative breast cancers.